HOME >> MEDICINE >> NEWS
Serendipity versus planning - cancer drugs of the future?

Delegates at the European Breast Cancer Conference (EBCC-5) were given two examples of promising new drugs to watch in the future - raloxifene and lapatinib.

New anticancer drugs are usually developed specially for the job, but occasionally they are borrowed from another field of medicine, and applied speculatively in cancer. Tamoxifen was designed as an anti-oestrogen, based on the observation that at least a third of breast cancers depend on female sex hormones such as oestrogen for survival. Tamoxifen has shown to be an exceptionally effective molecule in cancer treatment; It was never planned to be a preventive agent, but so it has proved to be! It is now licensed to be used to prevent breast cancer in certain women at high risk of the disease.

Contrast this with raloxifene, a drug first developed to treat osteoporosis in women. A selective benzothiophene oestrogen receptor modulator (SERM), raloxifene binds to oestrogen receptors as a mixed oestrogen and anti-oestrogen effect. It functions as an oestrogen sometimes (in bones and on lipid metabolism) and as an anti-oestrogen in other target tissues (endometrium and breast). So, it has the potential for producing some of oestrogen's beneficial effects without producing its adverse effects. In a trial of its use in osteoporosis, it appeared to have another completely different effect, namely prevention of new hormone dependant breast cancers.

Results from the MORE (The Multiple Outcomes of Raloxifene Evaluation) study of 7,705 women that were randomised to raloxifene or placebo demonstrated that among postmenopausal women with osteoporosis, the risk of invasive breast cancer was decreased by 76% during three years of treatment with raloxifene.

Stronger evidence on the safety and efficacy of raloxifene is awaited from the STAR Trial. This trial includes almost 20,000 postmenopausal women in the US who are at increased risk of breast cancer to determine whether raloxifene is as e
'"/>

Contact: EBCC-5 Press Office
stephanie.makin@toniclc.com
33-493-928-402
Federation of European Cancer Societies
24-Mar-2006


Page: 1 2 3

Related medicine news :

1. Experts predict Tamiflu could halve the pandemic influenza death toll versus no intervention
2. Quality versus quantity -- transforming kidney transplant policy
3. Fixed versus growth intelligence mindsets: Its all in your head, Dweck says
4. Mechanism of black cohosh versus hot flashes revealed
5. IMRT versus 3D CRT for prostate cancer, new long-term data assesses side effects
6. Adolescent condom use with casual versus main partners
7. Study shows rituximab effective in treating chronic graft-versus-host disease
8. Gap widens between optimal versus actual cholesterol levels
9. CT colonography versus colonoscopy for colorectal cancer
10. The economics of prescription drugs versus OTC
11. Inverse planning system improves brachytherapy treatment for prostate and other cancers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Serendipity versus planning cancer drugs the future

(Date:7/29/2014)... 2014 DailyGossip.org reveals in its Stop ... a new method of naturally overcoming sciatica, in less ... new method ensure sufferers that the cure is simple ... , The new method is described as very fast, ... with an 8 minutes per day treatment plan. ...
(Date:7/29/2014)... July 29, 2014 Parker Waichman LLP, ... of victims injured by defective drugs and medical devices, ... by plaintiffs in Canada who allege that they were ... with the low testosterone injection Delatestryl (Court File ... 2014 in the Ontario Superior Court of Justice. , ...
(Date:7/29/2014)... Daily Gossip writes in its Fibroids Miracle ... that will teach users how to permanently eliminate uterine fibroids. ... from all over the world. , They have been ... in as quickly as 12 hours. This means that pain ... , The Fibroids Miracle review also indicates that the ...
(Date:7/29/2014)... Daily Gossip indicates in its Natural Vitiligo Treatment ... a popular nutritionist and health specialist. Michael Dawson suffered ... disorder, but none of them worked. , According to ... to look for an alternative vitiligo treatment, which he ... too, to become vitiligo free. , To learn ...
(Date:7/29/2014)... (HealthDay News) --,The time at which heart attack patients ... survival, new research suggests. Showing up at the ... is associated with a 13 percent higher risk for ... Every year, more than 250,000 people suffer a ... heart attack, which is caused by a complete blockage ...
Breaking Medicine News(10 mins):Health News:Stop Sciatica in 8 Minutes Review Reveals the Way to Cure Sciatica Easily 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 3Health News:Amanda Leto’s Fibroids Miracle Review Reveals Clinically Proven Uterine Fibroids Cure System 2Health News:Natural Vitiligo Treatment System Review Reveals Michael Dawson’s New Vitiligo Cure Program 2Health News:Heart Attack Patients Treated at Night, Weekends May Have Worse Outcomes 2
(Date:7/29/2014)... LAUDERDALE, Fla. , July 29, 2014 /PRNewswire-iReach/ ... medical service provider, has launched its Medical ... Program.  These services are tailored to the ... excellent standards prompted industry operators to propose that ... MHG Medical,s new program is intended to ...
(Date:7/29/2014)... 29, 2014  Instrumentation Laboratory (IL) today announced the launch ... logo. This is part of a comprehensive rebranding effort by ... Boston, MA , in 1959, IL has ... 1992.  Other companies in the group include Inova Diagnostics ( ... Barcelona, Spain ).  Like IL, these three companies ...
(Date:7/29/2014)... 2014 Cynosure, Inc. (Nasdaq: ... light-based aesthetic treatment systems for high-volume applications, today reported ... 2014. Second-quarter 2014 financial results incorporate the acquisition of ... 2013. Second-Quarter 2014 Financial Highlights ... $72.6 million , Non-GAAP net income of $7.1 ...
Breaking Medicine Technology:MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12
Cached News: